Suchen
Xencor Inc
XNCRZur Watchlist hinzufügen
11.220USD
-0.660-5.56%
Handelsschluss 05/15, 16:00（ET）Kurse um 15 Minuten verzögert
831.87MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Xencor Inc Unternehmen
Xencor, Inc. is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases. It has more than 20 candidates engineered with its XmAb technology that are in clinical development, and multiple XmAb medicines are marketed by partners. Its XmAb engineering technology enables small changes to a protein structure that result in new mechanisms of therapeutic action. Its wholly-owned development candidates include XmAb942, XmAb819, XmAb808, and XmAb541. Candidates co-developed with partners include Plamotamab. Its clinical-stage drug candidates advanced by partners include Xaluritamig (AMG 509), ASP2138, JNJ-9401, JNJ-1493, Xpro1595, Obexelimab, and Novartis XmAb, an undisclosed antibody candidate. Its cytokine drug candidates in clinical development consist of efbalropendekin alfa (XmAb306/RG6323). Its Vudalimab is a bispecific antibody that targets PD-1 and CTLA-4.
Xencor Inc Informationen
BörsenkürzelXNCR
Name des UnternehmensXencor Inc
IPO-datumDec 03, 2013
CEODahiyat (Bassil I)
Anzahl der mitarbeiter250
WertpapierartOrdinary Share
GeschäftsjahresendeDec 03
Addresse465 N. Halstead St.
StadtPASADENA
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl91107
Telefon16263055900
Websitehttps://xencor.com/
BörsenkürzelXNCR
IPO-datumDec 03, 2013
CEODahiyat (Bassil I)
Führungskräfte von Xencor Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. John R. Desjarlais, Ph.D.
Dr. John R. Desjarlais, Ph.D.
Executive Vice President - Research, Chief Scientific Officer
Executive Vice President - Research, Chief Scientific Officer
231.70K
+6.74%
Ms. Celia E. Eckert
Ms. Celia E. Eckert
Senior Vice President, General Counsel, Corporate Secretary
Senior Vice President, General Counsel, Corporate Secretary
57.51K
+21.17%
Mr. Bart Jan Cornelissen
Mr. Bart Jan Cornelissen
Senior Vice President, Chief Financial Officer
Senior Vice President, Chief Financial Officer
48.35K
-7.24%
Mr. Kurt A. Gustafson
Mr. Kurt A. Gustafson
Independent Director
Independent Director
6.50K
-118.52%
Mr. Richard J. (Rich) Ranieri
Mr. Richard J. (Rich) Ranieri
Independent Director
Independent Director
5.50K
-140.08%
Dr. Bassil I. Dahiyat, Ph.D.
Dr. Bassil I. Dahiyat, Ph.D.
President, Chief Executive Officer, Founder and Director
President, Chief Executive Officer, Founder and Director
--
--
Dr. A. Bruce Montgomery, M.D.
Dr. A. Bruce Montgomery, M.D.
Lead Independent Director
Lead Independent Director
--
--
Dr. Kevin C. Gorman, Ph.D.
Dr. Kevin C. Gorman, Ph.D.
Independent Director
Independent Director
--
--
Dr. Ellen Gwen Feigal, M.D.
Dr. Ellen Gwen Feigal, M.D.
Independent Director
Independent Director
--
--
Dr. Barbara J. Klencke, M.D.
Dr. Barbara J. Klencke, M.D.
Independent Director
Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. John R. Desjarlais, Ph.D.
Dr. John R. Desjarlais, Ph.D.
Executive Vice President - Research, Chief Scientific Officer
Executive Vice President - Research, Chief Scientific Officer
231.70K
+6.74%
Ms. Celia E. Eckert
Ms. Celia E. Eckert
Senior Vice President, General Counsel, Corporate Secretary
Senior Vice President, General Counsel, Corporate Secretary
57.51K
+21.17%
Mr. Bart Jan Cornelissen
Mr. Bart Jan Cornelissen
Senior Vice President, Chief Financial Officer
Senior Vice President, Chief Financial Officer
48.35K
-7.24%
Mr. Kurt A. Gustafson
Mr. Kurt A. Gustafson
Independent Director
Independent Director
6.50K
-118.52%
Mr. Richard J. (Rich) Ranieri
Mr. Richard J. (Rich) Ranieri
Independent Director
Independent Director
5.50K
-140.08%
Dr. Bassil I. Dahiyat, Ph.D.
Dr. Bassil I. Dahiyat, Ph.D.
President, Chief Executive Officer, Founder and Director
President, Chief Executive Officer, Founder and Director
--
--
Umsatzaufteilung
Währung: USDAktualisiert: Mon, Apr 6
Währung: USDAktualisiert: Mon, Apr 6
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Royalties
80.28M
63.93%
Milestone
45.30M
36.07%
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Royalties
80.28M
63.93%
Milestone
45.30M
36.07%
Aktionärsstatistik
Aktualisiert: Sun, May 10
Aktualisiert: Sun, May 10
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
BlackRock Institutional Trust Company, N.A.
14.38%
PRIMECAP Management Company
13.94%
BVF Partners L.P.
9.62%
RTW Investments L.P.
9.14%
RA Capital Management, LP
6.39%
Andere
46.52%
Aktionäre
Aktionäre
Anteil
BlackRock Institutional Trust Company, N.A.
14.38%
PRIMECAP Management Company
13.94%
BVF Partners L.P.
9.62%
RTW Investments L.P.
9.14%
RA Capital Management, LP
6.39%
Andere
46.52%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
54.03%
Investment Advisor/Hedge Fund
32.00%
Hedge Fund
18.37%
Venture Capital
7.44%
Research Firm
5.09%
Individual Investor
1.17%
Pension Fund
0.85%
Bank and Trust
0.38%
Insurance Company
0.03%
Institutionelle Beteiligung
Aktualisiert: Wed, Apr 1
Aktualisiert: Wed, Apr 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2026Q4
364
84.79M
119.03%
--
2026Q1
448
94.73M
127.77%
+2.75K
2025Q4
446
84.30M
118.05%
-5.40M
2025Q3
434
80.43M
112.65%
-6.04M
2025Q2
437
81.68M
114.52%
-1.81M
2025Q1
459
80.70M
113.40%
-3.00M
2024Q4
454
76.54M
108.64%
-2.55M
2024Q3
455
73.66M
105.55%
+3.66M
2024Q2
436
65.64M
106.20%
-4.06M
2024Q1
431
66.91M
108.52%
-498.74K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
BlackRock Institutional Trust Company, N.A.
10.66M
14.54%
+80.73K
+0.76%
Dec 31, 2025
PRIMECAP Management Company
10.22M
13.93%
-456.70K
-4.28%
Dec 31, 2025
BVF Partners L.P.
7.13M
9.73%
+2.51M
+54.43%
Dec 31, 2025
RTW Investments L.P.
6.78M
9.24%
+556.41K
+8.94%
Dec 31, 2025
RA Capital Management, LP
4.74M
6.46%
+4.74M
--
Mar 23, 2026
State Street Investment Management (US)
4.51M
6.15%
+833.42K
+22.69%
Dec 31, 2025
EcoR1 Capital, LLC
3.25M
4.43%
-2.89M
-47.09%
Dec 31, 2025
TCG Crossover Management, LLC
2.45M
3.34%
--
--
Dec 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Dec 6
Aktualisiert: Sat, Dec 6
Name
Anteil
iShares Genomics Immunology and Healthcare ETF
2.09%
Tema Oncology ETF
1.16%
Virtus LifeSci Biotech Clinical Trials ETF
1.06%
Invesco NASDAQ Future Gen 200 ETF
0.97%
Invesco S&P SmallCap Health Care ETF
0.64%
ALPS Medical Breakthroughs ETF
0.43%
State Street SPDR S&P Biotech ETF
0.33%
Inspire Small/Mid Cap ESG ETF
0.3%
Direxion Daily S&P Biotech Bull 3X Shares
0.15%
ProShares Ultra Nasdaq Biotechnology
0.15%
Mehr Anzeigen
iShares Genomics Immunology and Healthcare ETF
Anteil2.09%
Tema Oncology ETF
Anteil1.16%
Virtus LifeSci Biotech Clinical Trials ETF
Anteil1.06%
Invesco NASDAQ Future Gen 200 ETF
Anteil0.97%
Invesco S&P SmallCap Health Care ETF
Anteil0.64%
ALPS Medical Breakthroughs ETF
Anteil0.43%
State Street SPDR S&P Biotech ETF
Anteil0.33%
Inspire Small/Mid Cap ESG ETF
Anteil0.3%
Direxion Daily S&P Biotech Bull 3X Shares
Anteil0.15%
ProShares Ultra Nasdaq Biotechnology
Anteil0.15%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
